{"id":575,"date":"2020-04-30T03:18:53","date_gmt":"2020-04-30T03:18:53","guid":{"rendered":"\/\/smallcapscn.x5view.co\/?p=575"},"modified":"2023-08-29T17:45:05","modified_gmt":"2023-08-29T17:45:05","slug":"paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients","status":"publish","type":"post","link":"https:\/\/smallcapscn.x5view.co\/?p=575","title":{"rendered":"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005"},"content":{"rendered":"<p><a href=\"http:\/\/smallcaps-production.test\/stocks\/?symbol=PAR&amp;lang=cn\">Paradigm Biopharmaceuticals (ASX: PAR)<\/a>\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002<\/p>\n<p>\u6269\u5927\u83b7\u53d6\u9879\u76ee\u4e5f\u88ab\u79f0\u4e3a\u201c\u540c\u60c5\u4f7f\u7528\u201d\uff0c\u5b83\u4e3a\u533b\u751f\u63d0\u4f9b\u4e86\u4f7f\u7528\u8c03\u67e5\u836f\u7269\u3001\u751f\u7269\u5236\u5242\u548c\u533b\u7597\u8bbe\u5907\u7684\u9014\u5f84\u3002<\/p>\n<p>\u8fd9\u4e9b\u53ef\u4ee5\u7528\u6765\u6cbb\u7597\u4e25\u91cd\u75be\u75c5\u7684\u60a3\u8005\uff0c\u76ee\u524d\u6ca1\u6709\u4e00\u4e2a\u4ee4\u4eba\u6ee1\u610f\u7684\u9009\u62e9\u3002<\/p>\n<p>\u5728\u8be5\u9879\u76ee\u4e0b\uff0cParadigm\u80fd\u591f\u6cbb\u759710\u4f8bZilosul\u6027\u819d\u9aa8\u5173\u8282\u708e\u60a3\u8005\uff0c10\u4f8b\u60a3\u8005\u73b0\u5df2\u5b8c\u6210\u6cbb\u7597\u3002<\/p>\n<p>\u6700\u540e\u4e00\u6b21\u8bc4\u4f30\u5c06\u5728\u6bcf\u4e2a\u75c5\u4eba\u63a5\u53d7\u6700\u540e\u4e00\u6b21\u6ce8\u5c04\u540e6\u5468\u8fdb\u884c\u3002<\/p>\n<p>Paradigm\u9884\u8ba1\uff0c\u5b83\u5c06\u57289\u6708\u4efd\u7684\u5b63\u5ea6\u516c\u5e03\u6765\u81ea\u8be5\u8ba1\u5212\u7684\u6570\u636e\u3002<\/p>\n<p>Paradigm\u516c\u53f8\u9996\u5e2d\u6267\u884c\u5b98Paul Rennie\u8bf4:\u201cParadigm\u5bf9\u53d6\u5f97\u8fd9\u4e00\u91cc\u7a0b\u7891\u5f0f\u7684\u8fdb\u5c55\u611f\u5230\u5174\u594b\uff0c\u7279\u522b\u662f\u5728\u51a0\u72b6\u75c5\u6bd2\u76ee\u524d\u7684\u5065\u5eb7\u72b6\u51b5\u4e0b\uff0c\u5e76\u611f\u8c22\u6240\u6709\u53c2\u4e0e\u6269\u5927\u83b7\u53d6\u9879\u76ee\u7684\u4eba\u5458\u5bf9\u6cbb\u7597\u9879\u76ee\u7684\u6301\u7eed\u52aa\u529b\u3002\u201d<\/p>\n<h2>MPS-1\u548cMPS-VI\u7684\u5b64\u513f\u836f<\/h2>\n<p>\u9664\u4e86\u5728\u9aa8\u5173\u8282\u708e\u60a3\u8005\u4e2d\u63a8\u5e7fZilosul\u836f\u7269\u5916\uff0cParadigm\u8fd8\u83b7\u5f97\u4e86\u4f7f\u7528\u8be5\u836f\u7269\u6cbb\u7597MPS-I\u548cMPS-VI\u7684\u7f55\u89c1\u75c5\u5b64\u513f\u836f\u79f0\u53f7\uff0c\u8fd9\u5c06\u4e3a\u5408\u683c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u63d0\u4f9b\u7a0e\u6536\u62b5\u514d\u3001\u8d39\u7528\u51cf\u514d\uff0c\u5e76\u5728\u83b7\u5f97\u6279\u51c6\u540e\u83b7\u5f977\u5e74\u7684\u5e02\u573a\u72ec\u5bb6\u7ecf\u8425\u6743\u3002<\/p>\n<p>\u6839\u636e\u8303\u578b\uff0cMPS-I\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u4ee3\u8c22\u6027\u75be\u75c5\uff0c\u662f\u7531\u9057\u4f20\u7f3a\u9677\u5f15\u8d77\u7684\u3002\u5b83\u4f1a\u5bfc\u81f4\u9aa8\u9abc\u53d1\u80b2\u5f02\u5e38\u3001\u751f\u957f\u8fdf\u7f13\u3001\u5fc3\u810f\u548c\u547c\u5438\u7cfb\u7edf\u75be\u75c5\uff0c\u6709\u65f6\u8fd8\u4f1a\u5bfc\u81f4\u8ba4\u77e5\u969c\u788d\u3002<\/p>\n<p>\u540c\u65f6\uff0cMPS-VI\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u5e38\u67d3\u8272\u4f53\u9690\u6027\u9057\u4f20\u75be\u75c5\uff0c\u53ef\u5bfc\u81f4\u6eb6\u9176\u4f53\u4e2d\u7cd6\u80fa\u805a\u7cd6\u7684\u79ef\u7d2f\u548c\u7269\u7406\u8868\u73b0\u3002<\/p>\n<p>\u76ee\u524d\u5bf9MPS\u60a3\u8005\u7684\u6cbb\u7597\u5305\u62ec\u9176\u66ff\u4ee3\u6cbb\u7597(ERT)\uff0c\u5b83\u53ef\u4ee5\u51cf\u5c11\u975e\u795e\u7ecf\u75c7\u72b6\u548c\u75bc\u75db\u3002\u7136\u800c\uff0c\u8fd9\u4e9b\u75c5\u4eba\u7ee7\u7eed\u62a5\u544a\u6301\u7eed\u7684\u50f5\u786c\u3001\u75bc\u75db\u3001\u708e\u75c7\u4ee5\u53ca\u5fc3\u810f\u548c\u6c14\u9053\u8f6f\u7ec4\u7ec7\u7684\u8868\u73b0\u3002<\/p>\n<p>Paradigm\u6307\u51fa\uff0c\u8fd9\u4e9b\u6cbb\u7597\u65b9\u6cd5\u4e0d\u8db3\u4ee5\u62b5\u6d88\u75bc\u75db\uff0c\u5e76\u58f0\u79f0\u5176iPPS\u836f\u7269\u53ef\u80fd\u662f\u4e00\u4e2a\u6709\u6548\u7684\u8f85\u52a9\u6216\u4e0eERT\u8054\u5408\u6cbb\u7597\u3002<\/p>\n<p>\u5728\u7f8e\u56fd\uff0c\u6709\u8d85\u8fc71.3\u4e07\u540dMPS\u60a3\u8005\uff0cParadigm\u9884\u6d4b\u5176iPPS\u5728\u8fd9\u4e00\u9886\u57df\u6bcf\u5e74\u7684\u6f5c\u5728\u5e02\u573a\u57286.05\u4ebf\u7f8e\u5143\u523013\u4ebf\u7f8e\u5143\u4e4b\u95f4\u3002<\/p>\n<p>Paradigm\u6b63\u51c6\u5907\u5f00\u5c55\u4e00\u9879\u8bd5\u70b9\u4e34\u5e8a\u9879\u76ee\uff0c\u5bf9\u63a5\u53d7ERT\u6216\u9aa8\u9ad3\u79fb\u690d\u540e\u4ecd\u6709\u75c7\u72b6\u7684MPS-I\u60a3\u8005\u8fdb\u884ciPPS\u8bc4\u4f30\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002 \u6269\u5927\u83b7\u53d6\u9879\u76ee\u4e5f\u88ab\u79f0\u4e3a\u201c\u540c\u60c5\u4f7f\u7528\u201d\uff0c\u5b83\u4e3a\u533b\u751f\u63d0\u4f9b\u4e86\u4f7f\u7528\u8c03\u67e5\u836f\u7269\u3001\u751f\u7269\u5236\u5242\u548c\u533b\u7597\u8bbe\u5907\u7684\u9014\u5f84\u3002 \u8fd9\u4e9b\u53ef\u4ee5\u7528\u6765\u6cbb\u7597\u4e25\u91cd\u75be\u75c5\u7684\u60a3\u8005\uff0c\u76ee\u524d\u6ca1\u6709\u4e00\u4e2a\u4ee4\u4eba\u6ee1\u610f\u7684\u9009\u62e9\u3002 \u5728\u8be5\u9879\u76ee\u4e0b\uff0cParadigm\u80fd\u591f\u6cbb\u759710\u4f8bZilosul\u6027\u819d\u9aa8\u5173\u8282\u708e\u60a3\u8005\uff0c10\u4f8b\u60a3\u8005\u73b0\u5df2\u5b8c\u6210\u6cbb\u7597\u3002 \u6700\u540e\u4e00\u6b21\u8bc4\u4f30\u5c06\u5728\u6bcf\u4e2a\u75c5\u4eba\u63a5\u53d7\u6700\u540e\u4e00\u6b21\u6ce8\u5c04\u540e6\u5468\u8fdb\u884c\u3002 Paradigm\u9884\u8ba1\uff0c\u5b83\u5c06\u57289\u6708\u4efd\u7684\u5b63\u5ea6\u516c\u5e03\u6765\u81ea\u8be5\u8ba1\u5212\u7684\u6570\u636e\u3002 Paradigm\u516c\u53f8\u9996\u5e2d\u6267\u884c\u5b98Paul Rennie\u8bf4:\u201cParadigm\u5bf9\u53d6\u5f97\u8fd9\u4e00\u91cc\u7a0b\u7891\u5f0f\u7684\u8fdb\u5c55\u611f\u5230\u5174\u594b\uff0c\u7279\u522b\u662f\u5728\u51a0\u72b6\u75c5\u6bd2\u76ee\u524d\u7684\u5065\u5eb7\u72b6\u51b5\u4e0b\uff0c\u5e76\u611f\u8c22\u6240\u6709\u53c2\u4e0e\u6269\u5927\u83b7\u53d6\u9879\u76ee\u7684\u4eba\u5458\u5bf9\u6cbb\u7597\u9879\u76ee\u7684\u6301\u7eed\u52aa\u529b\u3002\u201d MPS-1\u548cMPS-VI\u7684\u5b64\u513f\u836f \u9664\u4e86\u5728\u9aa8\u5173\u8282\u708e\u60a3\u8005\u4e2d\u63a8\u5e7fZilosul\u836f\u7269\u5916\uff0cParadigm\u8fd8\u83b7\u5f97\u4e86\u4f7f\u7528\u8be5\u836f\u7269\u6cbb\u7597MPS-I\u548cMPS-VI\u7684\u7f55\u89c1\u75c5\u5b64\u513f\u836f\u79f0\u53f7\uff0c\u8fd9\u5c06\u4e3a\u5408\u683c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u63d0\u4f9b\u7a0e\u6536\u62b5\u514d\u3001\u8d39\u7528\u51cf\u514d\uff0c\u5e76\u5728\u83b7\u5f97\u6279\u51c6\u540e\u83b7\u5f977\u5e74\u7684\u5e02\u573a\u72ec\u5bb6\u7ecf\u8425\u6743\u3002 \u6839\u636e\u8303\u578b\uff0cMPS-I\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u4ee3\u8c22\u6027\u75be\u75c5\uff0c\u662f\u7531\u9057\u4f20\u7f3a\u9677\u5f15\u8d77\u7684\u3002\u5b83\u4f1a\u5bfc\u81f4\u9aa8\u9abc\u53d1\u80b2\u5f02\u5e38\u3001\u751f\u957f\u8fdf\u7f13\u3001\u5fc3\u810f\u548c\u547c\u5438\u7cfb\u7edf\u75be\u75c5\uff0c\u6709\u65f6\u8fd8\u4f1a\u5bfc\u81f4\u8ba4\u77e5\u969c\u788d\u3002 \u540c\u65f6\uff0cMPS-VI\u662f\u4e00\u79cd\u7f55\u89c1\u7684\u5e38\u67d3\u8272\u4f53\u9690\u6027\u9057\u4f20\u75be\u75c5\uff0c\u53ef\u5bfc\u81f4\u6eb6\u9176\u4f53\u4e2d\u7cd6\u80fa\u805a\u7cd6\u7684\u79ef\u7d2f\u548c\u7269\u7406\u8868\u73b0\u3002 \u76ee\u524d\u5bf9MPS\u60a3\u8005\u7684\u6cbb\u7597\u5305\u62ec\u9176\u66ff\u4ee3\u6cbb\u7597(ERT)\uff0c\u5b83\u53ef\u4ee5\u51cf\u5c11\u975e\u795e\u7ecf\u75c7\u72b6\u548c\u75bc\u75db\u3002\u7136\u800c\uff0c\u8fd9\u4e9b\u75c5\u4eba\u7ee7\u7eed\u62a5\u544a\u6301\u7eed\u7684\u50f5\u786c\u3001\u75bc\u75db\u3001\u708e\u75c7\u4ee5\u53ca\u5fc3\u810f\u548c\u6c14\u9053\u8f6f\u7ec4\u7ec7\u7684\u8868\u73b0\u3002 Paradigm\u6307\u51fa\uff0c\u8fd9\u4e9b\u6cbb\u7597\u65b9\u6cd5\u4e0d\u8db3\u4ee5\u62b5\u6d88\u75bc\u75db\uff0c\u5e76\u58f0\u79f0\u5176iPPS\u836f\u7269\u53ef\u80fd\u662f\u4e00\u4e2a\u6709\u6548\u7684\u8f85\u52a9\u6216\u4e0eERT\u8054\u5408\u6cbb\u7597\u3002 \u5728\u7f8e\u56fd\uff0c\u6709\u8d85\u8fc71.3\u4e07\u540dMPS\u60a3\u8005\uff0cParadigm\u9884\u6d4b\u5176iPPS\u5728\u8fd9\u4e00\u9886\u57df\u6bcf\u5e74\u7684\u6f5c\u5728\u5e02\u573a\u57286.05\u4ebf\u7f8e\u5143\u523013\u4ebf\u7f8e\u5143\u4e4b\u95f4\u3002 Paradigm\u6b63\u51c6\u5907\u5f00\u5c55\u4e00\u9879\u8bd5\u70b9\u4e34\u5e8a\u9879\u76ee\uff0c\u5bf9\u63a5\u53d7ERT\u6216\u9aa8\u9ad3\u79fb\u690d\u540e\u4ecd\u6709\u75c7\u72b6\u7684MPS-I\u60a3\u8005\u8fdb\u884ciPPS\u8bc4\u4f30\u3002<\/p>\n","protected":false},"author":3,"featured_media":576,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[52],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v17.3 (Yoast SEO v21.0) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005<\/title>\n<meta name=\"description\" content=\"Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005\" \/>\n<meta property=\"og:description\" content=\"Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-30T03:18:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:45:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Paradigm-Biopharmaceuticals-Zilosul-osteoarthritis-program-trial-drug-MPS-patients-ASX-PAR-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lorna Nicholas\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005\" \/>\n<meta name=\"twitter:description\" content=\"Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lorna Nicholas\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/\",\"name\":\"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2020-04-30T03:18:53+00:00\",\"dateModified\":\"2023-08-29T17:45:05+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\"},\"description\":\"Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60\",\"name\":\"Lorna Nicholas\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g\",\"caption\":\"Lorna Nicholas\"},\"description\":\"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005","description":"Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005","og_description":"Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/","og_site_name":"smallcapsCN","article_published_time":"2020-04-30T03:18:53+00:00","article_modified_time":"2023-08-29T17:45:05+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Paradigm-Biopharmaceuticals-Zilosul-osteoarthritis-program-trial-drug-MPS-patients-ASX-PAR-1.jpg","type":"image\/jpeg"}],"author":"Lorna Nicholas","twitter_card":"summary_large_image","twitter_title":"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005","twitter_description":"Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002","twitter_misc":{"Written by":"Lorna Nicholas"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/","url":"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/","name":"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2020-04-30T03:18:53+00:00","dateModified":"2023-08-29T17:45:05+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60"},"description":"Paradigm Biopharmaceuticals (ASX: PAR)\u5df2\u7ecf\u5b8c\u6210\u4e86\u5176Zilosul\u6ce8\u5c04\u620a\u805a\u786b\u9178\u94a0(iPPS)\u836f\u7269\u5728\u7f8e\u56fdFDA\u7684\u6269\u5927\u51c6\u5165\u8ba1\u5212\u4e0b\u7684\u6cbb\u7597\uff0c\u540c\u65f6FDA\u5c06\u5176\u7528\u4e8eMPS-I\u6cbb\u7597\u7684\u5b64\u513f\u836f\u72b6\u6001\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/paradigm-biopharmaceuticals-zilosul-osteoarthritis-program-trial-drug-mps-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Paradigm Biopharmaceuticals\u6539\u8fdbZilosul\u9aa8\u5173\u8282\u708e\u8bbe\u8ba1\uff0c\u4ee5\u8bd5\u9a8c\u836f\u7269\u5728MPS\u60a3\u8005"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/3e816860d3443582b1918467347eeb60","name":"Lorna Nicholas","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/431dd83ad861252293034fed39d5d7a5?s=96&d=mm&r=g","caption":"Lorna Nicholas"},"description":"Lorna has more than 15 years' experience as a business\/finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.","url":"https:\/\/smallcapscn.x5view.co\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/575"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=575"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/575\/revisions"}],"predecessor-version":[{"id":7689,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/575\/revisions\/7689"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/576"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=575"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=575"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=575"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}